Needle-Free Compounded Semaglutide and Tirzepatide Tablets Offer Physician-Supervised, At-Home GLP-1 Treatment Access Through ...

A new class of weight-loss drug has shown it can significantly boost weight loss when paired with GLP-1 therapy – without ...

RJVA-002 achieved ~30% weight loss at five weeks in a translational obesity model; weight loss not yet plateauedPreclinical ...

Adults with obesity who reported more intense tastes while receiving semaglutide or tirzepatide had a higher likelihood for ...

Regeneron’s monoclonal antibody trevogrumab, with or without the anti-activin A antibody garetosmab, appears to preserve lean ...

"As of now, semaglutide is FDA-indicated for slowing chronic kidney disease progression, [but] our results suggest that liraglutide and dulaglutide may have similar kidney protection," she added.

While only two therapies have so far gained approval, the broader pipeline paints a picture of strong research and development activity.

Eli Lilly officially launched its first dual GIP and GLP-1 receptor agonist injection in mainland China on 23 December 2024, attracting significant market attention. The drug, MOUNJARO * (TIRZEPATID * ...

Dariush Mozaffarian, Monica Agarwal, Monica Aggarwal, Lydia Alexander, Caroline M. Apovian, Shagun Bindlis, Jonathan Bonnet, W. Scott Butsch, Sandra Christensen ...

Obesity is a major public health and economic challenge in the US, costing the health care system an estimated $173 billion ...

Patients with T2D and overweight/obesity starting GLP-1 therapy may experience a small but statistically significant increase ...

Pharmacist professor Luke Grzeskowiak said that these drugs can be useful, but they carry risks, particularly in pregnancy.